Birabresib Dose 20 mg
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AML Including AML de Novo and AML Secondary to MDS
Conditions
AML Including AML de Novo and AML Secondary to MDS, DLBCL
Trial Timeline
May 19, 2016 → Sep 9, 2021
NCT ID
NCT02698189About Birabresib Dose 20 mg
Birabresib Dose 20 mg is a phase 1 stage product being developed by Merck for AML Including AML de Novo and AML Secondary to MDS. The current trial status is terminated. This product is registered under clinical trial identifier NCT02698189. Target conditions include AML Including AML de Novo and AML Secondary to MDS, DLBCL.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02698189 | Phase 1 | Terminated |
Competing Products
11 competing products in AML Including AML de Novo and AML Secondary to MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HRS -8427 + Imipenem and Cilastatin Sodium | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| navitoclax + Rifampin | AbbVie | Phase 1 | 33 |
| AZD4573 | AstraZeneca | Phase 1 | 33 |
| LBH589 | Novartis | Phase 1 | 33 |
| HRO761 + pembrolizumab + irinotecan | Novartis | Phase 1 | 33 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral) | Pfizer | Phase 3 | 76 |
| Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral) | Pfizer | Phase 3 | 76 |
| ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine | Jazz Pharmaceuticals | Phase 2 | 49 |
| CUDC-907 | Curis | Phase 2 | 44 |